The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

November 12, 2019

Floor J. Backes, MD, discusses the safety profile from a phase I study looking at lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

November 12, 2019

Casey M. Cosgrove, MD, discusses factors to consider when selecting a PARP inhibitor as maintenance therapy in advanced ovarian cancer.

November 09, 2019

Leigha Senter, MS, LGC, discusses the implications of identifying genes beyond BRCA1/2 in women with ovarian cancer.

November 08, 2019

Floor J. Backes, MD, associate professor, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, discusses treatment selection with PARP inhibitors in ovarian cancer.

November 07, 2019

Jeffrey M. Fowler, MD, discusses factors used to determine whether a patient with advanced ovarian cancer is eligible for primary cytoreductive surgery.

November 05, 2019

David O’Malley, MD, discusses the toxicities associated with PARP inhibitors in ovarian cancer.

November 05, 2019

Floor J. Backes, MD, discusses the next steps regarding a phase I trial investigating lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

October 15, 2019

Floor J. Backes, MD, discusses the rationale and results from a phase I study exploring lenvatinib and weekly paclitaxel in women with recurrent endometrial cancer.

September 18, 2019

David Bond, MD, addresses the ongoing challenge of second primary neoplasia in chronic lymphocytic leukemia.

August 07, 2019

David A. Bond, MD, assistant professor, The Ohio State University, discusses the high rates of second cancers in both treatment-naïve and pretreated patients with chronic lymphocytic leukemia who received BTK inhibitors.

August 02, 2019

The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute announced formation of the Pelotonia Institute for Immuno-Oncology, a comprehensive bench-to-bedside research initiative focused on harnessing the body’s immune system to fight cancer at all levels—from prevention to treatment and survivorship.

July 29, 2019

Financial pledge from Pelotonia represents one of the largest gifts ever to The Ohio State University and honors the 2,265 riders who participated in the inaugural ride in 2009.

July 10, 2019

Jennifer Woyach, MD, discusses a 3-year follow-up looking at acalabrutinib with obinutuzumab in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia.

June 26, 2019

Jennifer Woyach, MD, discusses the 3-year follow-up from the single-arm study of the combination of acalabrutinib (Calquence) and obinutuzumab (Gazyva) showcase the efficacy of the regimen in both patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia and the future of treatment in the space.

November 29, 2018

David O’Malley, MD, discusses the findings from the SOLO-1 and QUADRA studies, as well as the future of PARP inhibition in ovarian cancer.

August 16, 2018

David O'Malley, MD, discusses the emerging combination of mirvetuximab soravtansine plus bevacizumab and the evolving treatment landscape in ovarian cancer.

August 10, 2018

David O'Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, discusses folate-receptor alpha as a biomarker in ovarian cancer.

July 26, 2018

Kerry Rogers, MD, assistant professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses reducing the risk of tumor lysis syndrome during the treatment of patients with chronic lymphocytic leukemia.

July 20, 2018

Alice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).

July 07, 2018

Symptoms of burnout continue to plague the physician community overall, but a recent survey suggests that factors such as resiliency and the ability to flourish can diminish its detrimental effects.